Neogen Chemicals Q3 FY26: Board Clears ₹150 Cr Raise

What the latest BSE disclosures indicate

Neogen Chemicals Ltd has filed multiple disclosures with BSE around board meetings, results, and planned investor interactions through February and March 2026. The central thread is the company’s Q3FY26 financial results approval and a parallel push to raise capital. The board meeting held on February 11, 2026 approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Alongside the results, the board granted in-principle approval for a preferential issue of equity shares to the promoter group, subject to regulatory clearances.

Separately, the company also intimated a board meeting scheduled for March 7, 2026 to consider and approve a proposal for raising funds through a preferential issue of equity shares and related matters. These steps, taken together, point to a capital planning exercise running in parallel with routine quarterly reporting. The filings also highlight several analyst and investor engagements, including conference calls and meets scheduled across February and March.

Board meeting outcome on February 11, 2026

Neogen Chemicals said its board meeting was convened on Wednesday, February 11, 2026, from 2:30 p.m. to 7:30 p.m. During this meeting, the board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company also noted the associated limited review report from its statutory auditors.

A key corporate action from the same meeting was the board’s in-principle approval for a fund raise via preferential issue of equity shares to the promoter group. The company stated this approval is subject to necessary regulatory sanctions. In addition, the company disclosed ESOP-related approvals handled through the Nomination and Remuneration Committee (NRC) on the same day.

Q3FY26 results: revenue disclosed for the quarter

In the results summary disclosed, Neogen Chemicals reported revenue from operations for the quarter at ₹215.60 crore. The filing also mentions a comparison figure of ₹200.41 crore “previously” for the same line item. Beyond revenue, the company’s disclosures referenced net profit margin for the quarter, but the specific margin number was not included in the text provided.

The company’s board approved both standalone and consolidated unaudited numbers for the quarter and the nine-month period ended December 31, 2025. Neogen also stated that the statutory auditors provided a limited review report for the results. The disclosure positions these approvals as part of the company’s Q3FY26 reporting cycle.

Exceptional loss linked to Dahej SEZ plant fire

The results disclosure included an exceptional item loss connected to a fire incident at the Dahej SEZ plant. Neogen Chemicals reported an exceptional item loss of ₹13.56 crore on a standalone basis and ₹14.08 crore on a consolidated basis.

The mention of this exceptional item is important because it separates the incident-linked impact from regular operating performance. The disclosure does not add further detail on timelines, operational disruption, or insurance treatment, and no additional numerical breakdown was provided in the text. Still, the explicit inclusion of the exceptional loss indicates the incident had a measurable effect on reported profitability for the period.

Preferential issue: in-principle approval up to ₹150 crore

The board granted in-principle approval to raise funds by issuing equity shares on a preferential basis to the promoter group. The aggregate amount was disclosed as up to ₹150 crore, inclusive of any premium determined by the board. The company said the proposed issuance would be pursuant to SEBI ICDR Regulations, 2018, and would remain subject to required regulatory approvals.

In a separate disclosure thread, Neogen Chemicals also informed BSE that a board meeting was scheduled on March 7, 2026 to consider and approve a proposal for raising funds through a preferential issue of equity shares and connected matters. In addition, the provided text also references an outcome dated April 13, 2026 that mentions approval to issue 1,000,000 equity shares on a preferential basis and approval of an EGM notice and related timelines.

ESOP approvals: options granted and vesting noted

Neogen Chemicals disclosed that its NRC met on February 11, 2026 and approved actions under the NCL ESOP Scheme 2024. The committee approved the grant of 50,200 stock options (Tranche-II) convertible into equity shares to 55 eligible employees.

The NRC also approved vesting of 4,650 employee stock options effective April 1, 2026. This vesting relates to the Tranche-I grant issued on April 1, 2025. The disclosure frames these as governance-led actions tied to employee retention and incentive structures, with specific quantities and effective dates stated.

Debt covenant update: security cover for ₹200 crore NCDs

The filing also referenced a certificate from independent auditors on compliance with debt covenants as of December 31, 2025 for ₹200 crore NCDs listed on BSE. The auditors confirmed, on a prima facie basis, that covenants were complied with and that the book value of assets reflected the required security cover percentage.

Neogen Chemicals disclosed a Security Coverage Ratio (SCR) of 1.90 times for the ₹200 crore NCDs as of December 31, 2025 on a standalone basis. This disclosure is relevant for bondholders and equity investors tracking leverage and covenant headroom.

Trading window closure and investor interactions

Neogen Chemicals disclosed that a trading window closure commenced on January 1, 2026 and would end 48 hours after the declaration of the Q3FY26 results. The company linked this to SEBI (Prohibition of Insider Trading) Regulations, 2015 and its internal code.

On investor communications, the text mentions multiple analyst and investor interactions, including an earnings conference call scheduled for February 12, 2026. It also lists investor or analyst meets scheduled on February 23, 2026, March 9, 2026, and March 10, 2026. These events typically coincide with results season and corporate actions, and help investors understand management’s framing of reported numbers and capital decisions.

Stock move cited alongside the disclosures

The provided text noted that Neogen Chemicals’ share price moved down 2.50% from its previous close of Rs 1,497.20. The last traded price cited was Rs 1,459.80. The disclosure also listed dividend yield as 0.00%.

These figures provide a snapshot of market trading around the period of disclosures, though the text does not attribute the move to a specific trigger. The pricing information is presented as a data point alongside the board meeting and results-related updates.

Key facts table

Why the fund raise and covenant disclosures matter

The combination of an in-principle ₹150 crore preferential equity proposal and the detailed covenant and security cover disclosures signals that Neogen Chemicals is communicating both equity-side and credit-side positioning. Preferential equity issuance to the promoter group is a specific route of capital raising and, as disclosed, remains subject to regulatory approvals.

At the same time, the cited SCR of 1.90x for the ₹200 crore NCDs and auditor confirmation of covenant compliance indicate the company is also addressing debt market stakeholders. With an exceptional loss tied to the Dahej SEZ plant fire included in reported results, investors are likely to track how the company balances operational recovery, ongoing capital needs, and funding mix choices.

Conclusion

Neogen Chemicals’ February 11, 2026 board outcome combined routine Q3FY26 financial approvals with in-principle consent for up to ₹150 crore via a preferential equity issue to the promoter group. The disclosures also captured an exceptional loss linked to the Dahej SEZ plant fire, ESOP grants and vesting actions, and an SCR of 1.90x for its ₹200 crore NCDs.

Next, investors will watch for developments tied to the scheduled March 7, 2026 board meeting on the preferential issue proposal, and for further details from the company’s planned earnings call and analyst or investor meets across February and March 2026.